Simplifying Complexity

Specificity
at scale.

Sapient accelerates your discovery program through large scale identification of biomarkers.

Sapient logo shape

A drug candidate with an associated biomarker is 2-10x more likely1 to obtain FDA approval. To date, however, the discovery of circulating biomarkers has been limited.

Sapient’s technology-based approaches break free from the limitations of traditional methods, enabling large scale measurement of thousands of circulating molecules to rapidly identify key biomarkers that inform drug development – including diagnostic biomarkers, pharmacodynamic biomarkers, drug efficacy biomarkers, and more.

EXPLORE THE APPLICATIONS

One platform — a wealth of actionable insights delivered.

  • molecular biomarker molecular biomarkers

    Target Identification

    Identify the best molecular biomarkers or new target candidates with activity that can be modulated by a therapeutic.

  • biomarker of disease detection disease detection biomarker

    Early Disease Detection

    Identify individuals at high risk for disease, years before onset, to develop drugs that more effectively limit disease progression.

  • biomarker of disease progression disease progression biomarker

    Disease Progression

    Reveal unique pathways essential to progressive disease and sub-stratify patients according to rapid progressors.

  • molecular biomarker molecular biomarkers

    Assessment of Target Engagement

    Confirm pharmacological engagement of key targets.

  • clinical biomarker biomarker for clinical trials

    Patient Stratification / Companion Diagnostics

    Identify patients most likely to benefit from a specific therapeutic intervention, and develop CLIA-certified diagnostic assays as a companion to therapies.

  • biomarker of disease detection disease detection biomarker

    Safety Profiling

    Predict adverse drug responses to obtain a more accurate view of potential drug safety issues, earlier in development.

  • biomarker of disease progression disease progression biomarker

    Pharmacometrics and QSP

    Uncover specific biomarkers for dosing and timing to maximize efficiency of drug therapies.

  • molecular biomarker molecular biomarkers

    Clinical Trial Optimization

    Reduce the size and accelerate the speed of trials by identifying patients most likely to respond positively to the drug.

  • clinical biomarker biomarker for clinical trials

    Chemical Signatures of Disease

    Identify new drug targets by uncovering biological drivers of disease.

  • biomarker of disease detection disease detection biomarker

    Reagent Validation

    Obtain accurate and rapid measurement of drug composition and purity.